Simultaneous transcatheter edge-to-edge repair for mitral and tricuspid regurgitation achieved combined procedural success in 80% of cases, with no intraprocedural major adverse events.
Cohort (n=40)
No
Is simultaneous transcatheter edge-to-edge repair (TEER) safe and effective for reducing regurgitation in patients with coexisting severe mitral and tricuspid regurgitation?
Simultaneous TEER for coexisting severe mitral and tricuspid regurgitation is feasible and safe, achieving procedural success in 80% of patients and improving NYHA functional class at 1 year.
Background Mitral regurgitation (MR) and tricuspid regurgitation (TR) commonly coexist in patients with heart failure (HF). Their concomitant occurrence carries a much poorer prognosis than isolated valve disease. Transcatheter edge-to-edge repair (TEER) of MR and TR is safe and effective, but there is limited data on combined MR/TR TEER. Objective The study evaluates the safety and efficacy of combined TEER for MR and TR in a real-world cohort. Methods This retrospective safety and efficacy analysis included the first 40 patients treated with combined MR/TR TEER between 2019 and 2021 at our single tertiary care referral centre. Results Combined procedural success (MR reduction ≥2° and TR reduction ≥1°) was achieved in 80% of the cases. Simultaneous TEER was safe, with no intraprocedural death, myocardial infarction (MI), stroke, or major bleeding. At 1-year follow-up, the median New York Heart Association functional (NYHA) class improved by one grade; twelve patients (30%) died, and fourteen patients (35%) were hospitalized for HF. Procedural success and postprocedural residual MR ≤ 1° were associated with reduced 1-year mortality rates but not HF hospitalizations. Conclusion Combined MR/TR TEER is safe and reduces MR and TR in most patients, conferring a potential benefit regarding symptoms and prognosis. Randomized controlled trials (RCTs) are needed to rigorously evaluate combination therapy in this setting.
Gollmer et al. (Tue,) conducted a cohort in Coexisting severe mitral and tricuspid regurgitation in heart failure (n=40). Simultaneous transcatheter edge-to-edge repair (TEER) for MR and TR was evaluated on Combined procedural success (MR reduction ≥2° and TR reduction ≥1°). Simultaneous transcatheter edge-to-edge repair for mitral and tricuspid regurgitation achieved combined procedural success in 80% of cases, with no intraprocedural major adverse events.